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Antibiotic-Induced Thrombocytopenia in the ICU: Case Report of a Diagnostic Challenge
Spiro Khoury M.D., Nicholas C. Watson M.D.
Department of Anesthesiology, University of Massachusetts Medical School, Worcester, MA
Introduction Discussion
Thrombocytopenia is the most common coagulation problem in ICU patients and is 
an independent predictor of death among critically ill patients1. Thrombocytopenia 
is generally defined as a platelet count below 100,000/μl1. The causation is 
frequently multi-factorial and driven by six distinct mechanisms: increased 
consumption, hemodilution, decreased production, sequestration, pseudo-
thrombocytopenia, and increased destruction1. The differential diagnosis of acute 
thrombocytopenia in an ICU patient is extensive. After eliminating the more 
common etiologies, drug-induced thrombocytopenia (DITP) should be considered 
as an often overlooked yet easily reversible cause of thrombocytopenia2 Due to a 
“…when you have eliminated the impossible, whatever remains, 
however improbable, must be the truth.”  Sherlock Holmes6
After extensive investigation, the evidence points to DITP secondary to pip-tazo.  DITP 
related to pip-tazo is exceedingly uncommon, appearing in only 3 case reports and in 13 
patients specifically tested for antibodies at Blood Center of WI (BCW) over 10 years; 
furthermore, in the absence of a positive drug-induced anti-platelet antibody test it is even 
more rare7-10. Despite the lack of serological confirmation, a diagnosis of pip-tazo induced 
DITP can be made based on published clinical criteria12. Our patient’s episodes of 
Figure 1.  Thrombocytopenia & Antibiotics on Multiple Admissions                                       Figure 2.  Method of Investigation                                          
Pip-tazo
Vanco
LMWH
PF4 negative
HIT IgG negative
Criteria for evaluating a causal relationship between a drug and thrombocytopenia4:
1. Suspected drug administration preceded thrombocytopenia.  Complete and sustained resolution 
of thrombocytopenia after suspected drug discontinued.
2. Platelet count remained normal after discontinuation of suspected drug despite the resumption or
continuation of other drugs.
3. Alternative etiologies of thrombocytopenia were excluded.
4. Re-exposure to the suspected drug was followed by thrombocytopenia.
?Criteria 1.  Vanco, pip-tazo, and heparin products all preceded thrombocytopenia.
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lack of distinguishing clinical features and numerous other possible etiologies, 
diagnosis is often complex, requiring a multi-step approach3. We discuss the 
extensive workup of DITP in the context of this unusual case presentation.
Patient Presentation 
This is a 66 year old male with PMH of severe COPD, atrial fibrillation, and lung CA s/p 
upper lobectomy.  He was admitted on four separate occasions to our institution over a 
two year period with COPD exacerbation and suspected pneumonia. On each 
admission his presentation, workup, and treatment were similar. Repeatedly he was 
empirically treated with vancomycin (vanco) and piperacillin tazobactam (pip tazo) as 
thrombocytopenia met all four of the criteria outlined by Rousan et. al. (figure 2) which 
constitutes “definite” probability for drug induced etiology10.   Additional support is seen with 
the utilization of an adverse drug reaction (ADR) probability scale11. This case scored 11 
out of a possible 13 points, where a score of ≥9 is equated with a “definite” probability that 
his thrombocytopenia is due to an ADR.
A blood sample failed to show pip-tazo or vanco related anti-platelet antibodies when tested 
by immunofluorescent flow cytometry at BCW. However, there are several limitations to this 
test: These assays have high specificity but moderate sensitivity since a metabolite of the 
drug formed in-vivo may be responsible for DITP and not the primary drug itself12,13. 
Piperacillin is known to form metabolites which are not normally tested   BCW does not 
Pip-tazo
Vanco
LMWH
Thrombocytopenia resolved after the discontinuation of vanco and pip-tazo in 3 
admissions; however, on the 3/6/12 admission the thrombocytopenia improved after 
discontinuation of pip-tazo while vanco continued.  On the 12/11/11 admission platelets 
declined after vanco was stopped and only recovered when pip-tazo was discontinued.  
?Criteria 2.  An extensive list of home medications was screened.  Multiple home 
medications were continued throughout the admissions shown in figure 1 during the 
normalization of platelet count, thus exonerating them as the cause. Thrombocytopenia 
resolved and remained normalized while heparin products were administered, and HIT 
testing was negative on several tests; thus eliminating heparin as the causative factor.
?Criteria 3 Any alternate etiology of thrombocytopenia would need to fit the timeo u
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an initial course, and in each circumstance he developed thrombocytopenia in a 
strikingly homogenous temporal sequence. In every incident, platelets recovered only 
after the cessation of pip-tazo. On the third admission platelets continued to fall after 
vanco was stopped and pip-tazo was continued.  On the final admission his platelets 
rose after cessation of pip-tazo while vanco was continued, strongly indicating that pip-
tazo was the offending agent.  Common and rare causes of thrombocytopenia were 
absent and anemia and neutropenia did not develop. Admissions during which he did 
not receive these antibiotics were not associated with thrombocytopenia.  
.
routinely run a control sample along with a patient sample for piperacillin13. Additional 
confounding elements are introduced by the need to test separately for piperacillin and 
tazobactam.  Tazobactam induced antibodies are so rare that they are not normally tested 
for by BCW. Because piperacillin is essentially never administered without tazobactam, 
there is very low clinical relevance to testing these agents independently. Finally, piperacillin 
antibodies are known to have weak drug dependent interactions with normal platelets; 
however, there was no correlation shown between antibody strength measured by flow 
cytometry and the severity of thrombocytopenia12. Therefore, a negative test is possible 
despite clinically relevant thrombocytopenia.
Pip-tazo
Vanco
SCHAdmission: 3/28/10 4/17/11 12/11/11 3/6/12
COPD COPD COPD COPD
 .            
course of the acute drop in platelet counts shown in figure 1. Thus, many chronic and 
indolent causes of thrombocytopenia were eliminated from consideration.  A number of 
potential etiologies remained that were excluded by logic and investigation:
Potential Etiology1: Excluded on basis of:
Sepsis
Failed to meet criteria for two admissions.  Met sepsis criteria for one 
day on each of two admissions.  Clinically unlikely to be explanation as 
sepsis was either very mild or not present.
Disseminated Intravascular 
Coagulation
No change in coagulation values on any admission, suspicion clinically 
low
Thrombotic Thrombocytopenic Purpura Smears from each admission show no evidence of microangiopathic ( x
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Ultimately, there may be value in re-testing this patient for drug-induced antibodies at his 
next clinical encounter.  From a practical perspective, his providers should avoid pip-tazo or 
very closely monitor platelet count if a suitable alternative is unavailable.
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?PNA, 
cultures 
negative, BP 
stable
 
exacerbation, 
eColi PNA,  
BP stable
 
exacerbation, 
eColi PNA,  
BP stable
 
exacerbation, 
?PNA, 
cultures 
negative, BP 
stable
Initial Platelet Count 163 250 168 289
Platelet Nadir (% drop from 
initial) 45 (73%) 118 (52%) 47 (75%) 109 (63%)
EcchymosisPF4 negative
  hemolysis; absence of anemia, hct stable during thrombocytopenia
Heparin-induced thrombocytopenia5
Multiple HIT tests negative on different admissions, eliminated HIT type 
II.  HIT type I (non-immune mediated) would be unlikely to drop platelets 
below 100K and would be more transient than documented.  Patient 
had 3 admissions without thrombocytopenia while receiving heparin 
(data not shown). 
Dilution by fluid infusions Magnitude and persistence of platelet drop too great.  Platelet count dropped while hematocrit stabilized, which is not consistent with dilution.
Dilution by transfusions No transfusions during critical platelet drops.
Sample clotting/ EDTA-induced clot Platelet drop consistent across multiple samples at different times. 
Could be caused by pip tazo or vanco but time course from meds to3
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Abbreviations
BCW: Blood Center of Wisconsin Platelet & Neutrophil Immunology Laboratory
DITP: drug induced thrombocytopenia
ELISA: Enzyme Linked Immunosorbent  Assay
PMH: Past medical history
LMWH
Days to nadir following vanco 
and pip-tazo initial 
administration
6 7 5 1
1 day drop in platelet count 
after exposure to vanco and 
pip-tazo
18% 40% 12% 57%
Days to recovery to baseline 
platelet count 15 >15 >15 >7
Table 1.  Note the pattern of thrombocytopenia across four admissions for similar 
clinical presentation and therapy.
Slow bleed at PEG site
Bone marrow suppression
    -   ,       
platelet drop likey too rapid to be explained by marrow suppression.  No 
leukopenia or anemia on any admission.
Idiopathic Thrombocytopenic Purpura
Diagnosis of exclusion.  ITP marked by chronically low platelets, not 
acute drops and recovery.  Patient on steroids at baseline, which would 
be treatment for ITP if he had it.
?Criteria 4.  Re-exposure to vancomycin and to piperacillin-tazobactam was 
immediately followed by falling platelet count.
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PNA: pneumonia
COPD: Chronic Obstructiive Pulmonary Disease
CA: Cancer
s/p: status post
